BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT05162222
- Locations
- 🇺🇸
Covance Clinical Research Unit - Dallas, Dallas, Texas, United States
A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan
- Conditions
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 525
- Registration Number
- NCT05161325
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-29
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 100
- Registration Number
- NCT05136677
- Locations
- 🇨🇳
The First Affiliated Hospital of Zhengzhou Universtiy-Oncology department, Zhengzhou, Henan, China
🇨🇳Local Institution - 0012, Ningbo, Zhejiang, China
🇨🇳Beijing Cancer hospital-Thoracic Cancer Department A, Beijing, Beijing, China
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT05134948
- Locations
- 🇨🇳
Local Institution - 0001, Beijing, Beijing, China
🇨🇳Local Institution - 0002, Fuzhou, Fujian, China
A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe
- Conditions
- First Posted Date
- 2021-11-17
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 304
- Registration Number
- NCT05123950
- Locations
- 🇺🇸
Medical Data Analytics, Parsippany, New Jersey, United States
A Study of Adjuvant Melanoma Stakeholder Treatment Preferences
- Conditions
- First Posted Date
- 2021-11-10
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 294
- Registration Number
- NCT05115006
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
A Study to Evaluate BMS-986141 Added on to Aspirin or Ticagrelor or the Combination, on Thrombus Formation in a Thrombosis Chamber Model in Participants With Stable Coronary Artery Disease and Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 58
- Registration Number
- NCT05093790
- Locations
- 🇬🇧
Local Institution - 0001, Edinburgh, United Kingdom
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
- First Posted Date
- 2021-10-13
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT05076175
- Locations
- 🇩🇪
Local Institution - 0097, Leipzig, Sachsen, Germany
🇺🇸Local Institution - 0041, Phoenix, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 509
- Registration Number
- NCT05068609
- Locations
- 🇺🇸
Local Institution, Mount Laurel, New Jersey, United States
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
- Conditions
- First Posted Date
- 2021-10-04
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 232
- Registration Number
- NCT05065762
- Locations
- 🇺🇸
Local Institution, Morrisville, North Carolina, United States